Cell-mediated inflammatory response to AAV gene therapy in the retina

Cell-mediated inflammatory response to AAV gene therapy in the retina

Bibliographic Details
Main Authors:	Chandler, LC, Yusuf, IH, Ferry, H, McClements, ME, MacLaren, RE, Xue, K
Format:	Conference item
Language:	English
Published:	Elsevier 2020

Similar Items

Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
by: Chandler, LC, et al.
Published: (2021)

Minicircle delivery to the neural retina as a gene therapy approach
by: Staurenghi, F, et al.
Published: (2022)

Adeno-associated virus (AAV) dual vector strategies for gene therapy encoding large transgenes
by: McClements, M, et al.
Published: (2017)

Insights on the regeneration potential of Müller glia in the mammalian retina
by: Salman, A, et al.
Published: (2021)

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia?
by: Han, RC, et al.
Published: (2021)

Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element enhances AAV2-driven transduction of mouse and human retina
by: Patrício, M, et al.
Published: (2017)

Choroideremia: molecular mechanisms and development of AAV gene therapy
by: Patrício, M, et al.
Published: (2018)

Promoter orientation within an AAV-CRISPR vector affects Cas9 expression and gene editing efficiency
by: Fry, LE, et al.
Published: (2020)

Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina
by: Hickey, DG, et al.
Published: (2017)

Gene therapy for retinal disease.
by: McClements, M, et al.
Published: (2013)

Enhancement of adeno-associated viral (AAV) gene therapy using hydroxychloroquine in murine and human tissues
by: Chandler, L, et al.
Published: (2019)

Non-viral delivery of CRIPSR/Cas cargo to the retina using nanoparticles: current possibilities, challenges, and limitations
by: Salman, A, et al.
Published: (2022)

Immunomodulatory effects of hydroxychloroquine and chloroquine in viral infections and their potential application in retinal gene therapy
by: Chandler, L, et al.
Published: (2020)

Codon-optimized RPGR improves stability and efficacy of AAV8 gene therapy in two mouse models of X-linked retinitis pigmentosa
by: Fischer, MD, et al.
Published: (2017)

Gene Therapies in Clinical Development to Treat Retinal Disorders
by: McClements, ME, et al.
Published: (2024)

RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences
by: Fry, LE, et al.
Published: (2020)

Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo
by: Tolmachova, T, et al.
Published: (2013)

In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration.
by: Buch, P, et al.
Published: (2006)

Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa
by: Orlans, HO, et al.
Published: (2021)

Tetradecanoylphorbol-13-acetate (TPA) significantly increases AAV2/5 transduction of human neuronal cells in vitro
by: You, Q, et al.
Published: (2012)

Gene therapy for age-related macular degeneration
by: MacLaren, RE
Published: (2015)

An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4−/− mice
by: McClements, ME, et al.
Published: (2018)

The biological activity of AAV vectors for choroideremia gene therapy can be measured by in vitro prenylation of RAB6A
by: Patrício, M, et al.
Published: (2018)

Development of AAV-mediated gene therapy for autosomal recessive bestrophinopathy
by: Wood, S
Published: (2017)

Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector.
by: Barnard, A, et al.
Published: (2014)

Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo.
by: Tolmachova, T, et al.
Published: (2013)

RNA editing for Usher syndrome using CRISPR-Cas13
by: Fry, LE, et al.
Published: (2020)

Stem cell therapy and the retina.
by: Maclaren, R, et al.
Published: (2007)

Envisioning the development of a CRISPR-Cas mediated base editing strategy for a patient with a novel pathogenic CRB1 single nucleotide variant
by: Bellingrath, J-S, et al.
Published: (2022)

Impact of vital dyes on cell viability and transduction efficiency of AAV vectors used in retinal gene therapy surgery: an in vitro and in vivo analysis
by: Salvetti, A, et al.
Published: (2017)

In silico analysis of pathogenic CRB1 single nucleotide variants and their amenability to base editing as a potential lead for therapeutic intervention
by: Bellingrath, J-S, et al.
Published: (2021)

Tetradecanoylphorbol-13-acetate (TPA) significantly increases AAV2/5 transduction of human neuronal cells in vitro.
by: You, Q, et al.
Published: (2012)

Assessment of tropism and effectiveness of new primate-derived hybrid recombinant AAV serotypes in the mouse and primate retina
by: Charbel Issa, P, et al.
Published: (2013)

Single residue AAV capsid mutation improves transduction of photoreceptors in the Abca4-/- mouse and bipolar cells in the rd1 mouse and human retina ex-vivo
by: De Silva, S, et al.
Published: (2016)

AAV-mediated gene transfer of human X-linked inhibitor of apoptosis protects against oxidative cell death in human RPE cells
by: Shan, H, et al.
Published: (2011)

Optimizing an AAV-CRISPR system for retinal gene therapy
by: Stevanovic, M
Published: (2019)

Gene therapy for retinal dystrophies
by: Issa, P, et al.
Published: (2012)

CDHR1-related late-onset macular dystrophy: further insights
by: Yusuf, IH, et al.
Published: (2020)

Genome-editing strategies for treating human retinal degenerations
by: Quinn, J, et al.
Published: (2021)

Technique of retinal gene therapy: delivery of viral vector into the subretinal space
by: Xue, K, et al.
Published: (2017)